原始出處紀錄
重大申請已送件
Spruce Biosciences 計畫於 2026 年第四季提交 TA-ERT BLA
Spruce 表示正推進製造、監管互動及商業規劃，以支持 TA-ERT 於 2026 年第四季提交 BLA 的計畫。此申請將是 MPS IIIB 疾病修飾療法首項監管申請，目前尚無核准治療。該公司亦宣布現金流動性已強化至 2027 年下半年，以涵蓋提交及潛在核准所需。
關鍵事實
- 申報時間
- 2026年5月13日 下午12:05
- 事件
- 申請已送件
- 方向
- 中性
- 來源
- SEC 8-K
- 可信度
- 有出處
來源摘錄
EX-99.1 2 sprb-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates Long-Term TA-ERT Data Presented at the 22nd Annual WORLDSymposium™ Highlight Rapid and Durable Reduction of Heparan Sulfate and Stabilization of Cognitive Function in Patients with MPS IIIB Strengthened Leadership Team Across Commercial, Clinical Development, and Regulatory Functions to Support BLA Submission and Pre-Launch Readiness Closed Underwritten Public Offering for $69.0 Million in Gross Proceeds, Extending Cash Runway into the Second Half of 2027 and Beyond Anticipated Potential FDA Approval of TA-ERT Entered into Loan and Security Agreement with Avenue Capital for up to $50.0 Million in Term Loans to Strengthen Financial Flexibil